Results 61 to 70 of about 732,506 (308)

Circulating Tumors Cells as Biomarkers [PDF]

The Cancer Journal, 2011
Personalized cancer medicine requires the development of tumor-specific biomarkers to optimize selection of targeted therapies and to better assess response to therapy. Current efforts in several tumor types have shown that patients in whom circulating tumor cells (CTCs) are detected have an inferior prognosis relative to those in whom CTCs are not ...
Daniel C, Danila, Klaus, Pantel, Martin, Fleisher, Howard I, Scher   +3 more
openaire   +2 more sources

Aberrant Expression and Prognostic Potential of IL-37 in Human Lung Adenocarcinoma

Biomedicines, 2022
Interleukin-37 (IL-37) is a relatively new IL-1 family cytokine that, due to its immunoregulatory properties, has lately gained increasing attention in basic and translational biomedical research.
Panayiota Christodoulou, Theodora-Christina Kyriakou, Panagiotis Boutsikos, Maria Andreou, Yuan Ji, Damo Xu, Panagiotis Papageorgis, Maria-Ioanna Christodoulou   +7 more
doaj   +1 more source

A coordinate deregulation of microRNAs expressed in mucosa adjacent to tumor predicts relapse after resection in localized colon cancer [PDF]

, 2018
Up to 20% of colorectal cancer (CRC) node-negative patients develop loco-regional or distant recurrences within 5 years from surgery. No predictive biomarker able to identify the node-negative subjects at high risk of relapse after curative treatment is ...
Albertoni, Laura, Fassan, Matteo, Grassi, Angela, Mescoli, Claudia, Perilli, Lisa, Rugge, Massimo, Tessarollo, Sofia, Urso, Emanuele D. L., Zanovello, Paola   +8 more
core   +1 more source

Breast fine-needle aspiration cytology in the era of core-needle biopsy: what is its role? [PDF]

Journal of Pathology and Translational Medicine
Fine-needle aspiration cytology (FNAC) has long been recognized as a minimally invasive, cost-effective, and reliable diagnostic tool for breast lesions.
Ahrong Kim, Hyun Jung Lee, Jee Yeon Kim
doaj   +1 more source

CD44 as a tumor biomarker and therapeutic target [PDF]

Experimental Hematology & Oncology, 2020
AbstractCD44, a complex transmembrane glycoprotein, exists in multiple molecular forms, including the standard isoform CD44s and CD44 variant isoforms. CD44 participates in multiple physiological processes, and aberrant expression and dysregulation of CD44 contribute to tumor initiation and progression. CD44 represents a common biomarker of cancer stem
Hanxiao Xu, Mengke Niu, Xun Yuan, Kongming Wu, Aiguo Liu   +4 more
openaire   +3 more sources

The role of fibroblast growth factors in cell and cancer metabolism

FEBS Letters, EarlyView.
Fibroblast growth factor (FGF) signaling regulates crucial signaling cascades that promote cell proliferation, survival, and metabolism. Therefore, FGFs and their receptors are often dysregulated in human diseases, including cancer, to sustain proliferation and rewire metabolism.
Jessica Price, Chiara Francavilla
wiley   +1 more source

MicroRNAs As Biomarkers of Brain Tumors

Cancer Management and Research
Brain tumors still remain a deadly cancer that, in most cases, is difficult to diagnose at an earlier stage. Therefore, it is necessary to develop rapid, sensitive methods for detecting cancer biomarkers. Such a biomarker may be a microRNA which expression level in body fluids is strongly correlated with cancer.
Jelski W, Mroczko B
openaire   +4 more sources

The role of histone modifications in transcription regulation upon DNA damage

FEBS Letters, EarlyView.
This review discusses the critical role of histone modifications in regulating gene expression during the DNA damage response (DDR). By modulating chromatin structure and recruiting repair factors, these post‐translational modifications fine‐tune transcriptional programmes to maintain genomic stability.
Angelina Job Kolady, Siyao Wang
wiley   +1 more source

Biomarkers for Wilms Tumor: A Systematic Review [PDF]

Journal of Urology, 2016
Wilms tumor is the most common childhood renal malignancy and the fourth most common childhood cancer. Many biomarkers have been studied but there has been no comprehensive summary. We systematically reviewed the literature on biomarkers in Wilms tumor to quantify the prognostic implications of the presence of individual tumor markers.We searched for ...
Cone, Eugene B, Dalton, Stewart S, Van Noord, Megan, Tracy, Elizabeth T, Rice, Henry E, Routh, Jonathan C   +5 more
openaire   +4 more sources

PARP inhibitors elicit distinct transcriptional programs in homologous recombination competent castration‐resistant prostate cancer

Molecular Oncology, EarlyView.
PARP inhibitors are used to treat a small subset of prostate cancer patients. These studies reveal that PARP1 activity and expression are different between European American and African American prostate cancer tissue samples. Additionally, different PARP inhibitors cause unique and overlapping transcriptional changes, notably, p53 pathway upregulation.
Moriah L. Cunningham, Jasibel Vasquez‐Gonzalez, Samantha M. Barnada, Salome Tchotorlishvili, Latese Jones, Ryan Maguire, Genevieve Lewis, Kinza Rizwan, Jenny Deng, Salma Koachar, Drithi Patel, Hailey Shankle, Tessa Mulders, Namra Ajmal, Charalambos Solomides, Emad S. Alnemri, Teresa F. Alnemri, Ayesha A. Shafi, Leonard G. Gomella, Wm Kevin Kelly, Steven B. McMahon, Matthew J. Schiewer   +21 more
wiley   +1 more source